Bangladesh will be without pacer Marufa Akter for the white-ball tour of New Zealand, which includes three ODIs and three T20Is. The Bangladesh Cricket Board has chosen to prioritise her full recovery from a foot injury over a rushed return, with the squad departing Dhaka on December 4.
Tour Snapshot and Akter's Status
The tour covers six international matches across two formats. Akter will stay in Bangladesh to focus on rehabilitation rather than travel with the squad.
The board has described the decision as precautionary, given her standing in the national setup.
Tour and availability overview| Item | Detail |
|---|
| Opposition | New Zealand |
| ODIs | 3 |
| T20Is | 3 |
| Total matches | 6 |
| Team departure from Dhaka | December 4 |
| Akter's expected return to walking | First week of December |
The timeline is the key metric here. Akter is only expected to resume walking in the first week of December, which is the same period the team departs.
Nature of the Injury
Akter is dealing with bone erosion at the base of the fifth metatarsal in her right foot. The condition has reportedly worsened in recent weeks, and she is currently using an Aircast boot as part of her treatment.
Reports describe the problem as an ongoing ankle injury, with the pain recurring in that area.
Treatment Timeline So Far
Before the recent Australia tour, Akter received an injection to address the problem. The intervention did not produce the desired results.
Team management then rested her for the final match of that series.
Injury and treatment sequence| Stage | Development |
|---|
| Pre-Australia tour | Injection administered |
| During Australia tour | Rested for the final match |
| Recent weeks | Condition deteriorated |
| Current | Aircast boot and rehabilitation |
| First week of December | Expected to resume walking |
The sequence shows a failed short-term fix followed by a shift to a longer recovery plan. That approach is consistent with managing a bone-related issue conservatively.
What the BCB Has Said
A top BCB official was quoted by Cricbuzz explaining the reasoning. “She is unavailable for the tour of New Zealand as we don't want to rush her considering she is one of our premier cricketers,” the official said.
The source added that the board wants to ensure she can bowl without discomfort. Without full recovery, she would struggle to bowl at her natural strength.
Why Caution Makes Analytical Sense
A bowler returning at reduced pace or with lingering pain risks both performance decline and re-injury. The pain has already recurred once after treatment.
Protecting a long-term asset over a six-match series is a defensible workload decision. It also reduces the chance of a longer layoff later.
Impact on Bangladesh's Pace Attack
Akter is a right-arm medium-fast bowler who has established herself as a new-ball operator. She is capable of unsettling top-order batters and is regarded as a potential long-term leader of the pace attack.
Her absence removes a primary option with the new ball across both formats. Bangladesh will need to redistribute those early overs among the remaining seamers.
Areas affected by Akter's absence| Area | Likely effect |
|---|
| New-ball bowling | Loss of a specialist opening option |
| Top-order pressure | Fewer early-wicket threats |
| Pace leadership | Less experience in the unit |
| Matches affected | 6 (3 ODIs, 3 T20Is) |
Recovery Outlook
Her recovery trajectory suggests she could be available for international cricket in the weeks after the New Zealand series. That depends on rehabilitation continuing to progress as planned.
Key markers to watch include her return to walking, followed by a graded return to running and bowling. The board has not set a firm return date, which is typical for bone-related injuries.
Key Takeaways
Akter will miss all six matches of the New Zealand tour. The decision is preventive, based on a worsening metatarsal condition and a previously unsuccessful injection.
For Bangladesh, the short-term cost is reduced new-ball depth. The longer-term aim is to bring back a premier pace bowler at full capacity.